SABS
Price
$3.11Alerts
Change
+$0.04 (+1.30%)
Updated
Nov 11 closing price
Capitalization
275.69M
141 days until earnings call
Intraday BUY SELL Signals
VYGR
Price
$1.76Alerts
Change
-$0.07 (-3.83%)
Updated
Nov 11 closing price
Capitalization
114.92M
118 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SABS vs VYGR

SABS vs VYGR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SABS vs. VYGR commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SABS is a StrongBuy and VYGR is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for SABS with price predictions
Nov 10, 2026

SABS's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for SABS turned positive on October 21, 2026. Looking at past instances where SABS's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SABS's RSI Oscillator exited the oversold zone, 23 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SABS as a result. In 76 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.

Following a +5.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where SABS advanced for three days, in 165 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

SABS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 43 cases where SABS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.

SABS moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SABS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SABS entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. SABS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.284) is normal, around the industry mean (3.498). P/E Ratio (2.424) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SABS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for VYGR with price predictions
Nov 10, 2026

Momentum Indicator for VYGR turns positive, indicating new upward trend

VYGR saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In 85 of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VYGR's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 61 cases where VYGR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for VYGR just turned positive on October 30, 2026. Looking at past instances where VYGR's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.

Following a +15.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where VYGR advanced for three days, in 228 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

VYGR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VYGR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for VYGR entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.744) is normal, around the industry mean (3.498). P/E Ratio (-1.030) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.263) is also within normal values, averaging (440.869).

The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. VYGR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VYGR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
VYGR: Fundamental Ratings
VYGR
OUTLOOK RATING
1..100
11
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
85
P/E GROWTH RATING
1..100
12
SEASONALITY SCORE
1..100
49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SABSVYGR
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 13 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
71%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (SABS: $3.07 vs. VYGR: $1.83)
Brand notoriety: SABS and VYGR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SABS: 109% vs. VYGR: 77%
Market capitalization -- SABS: $275.69M vs. VYGR: $114.92M
SABS [@Biotechnology] is valued at $275.69M. VYGR’s [@Biotechnology] market capitalization is $114.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SABS’s FA Score shows that 0 FA rating(s) are green while VYGR’s FA Score has 1 green FA rating(s).

  • SABS’s FA Score: 0 green, 5 red.
  • VYGR’s FA Score: 1 green, 4 red.
According to our system of comparison, VYGR is a better buy in the long-term than SABS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SABS’s TA Score shows that 5 TA indicator(s) are bullish while VYGR’s TA Score has 6 bullish TA indicator(s).

  • SABS’s TA Score: 5 bullish, 4 bearish.
  • VYGR’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, VYGR is a better buy in the short-term than SABS.

Price Growth

SABS (@Biotechnology) experienced а -1.60% price change this week, while VYGR (@Biotechnology) price change was -0.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

SABS is expected to report earnings on Apr 01, 2027.

VYGR is expected to report earnings on Mar 09, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

VYGR and

Correlation & Price change

A.I.dvisor indicates that over the last year, VYGR has been loosely correlated with EDIT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if VYGR jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VYGR
1D Price
Change %
VYGR100%
-8.29%
EDIT - VYGR
60%
Loosely correlated
-8.91%
RCKT - VYGR
55%
Loosely correlated
-3.16%
DYN - VYGR
52%
Loosely correlated
-3.76%
MGTX - VYGR
50%
Loosely correlated
+1.37%
SLDB - VYGR
50%
Loosely correlated
+2.14%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FENY34.050.14
+0.41%
Fidelity MSCI Energy Index ETF (FENY)
MAYZ35.57N/A
N/A
TrueShares Structured Outcome (May) ETF (MAYZ)
SNOV27.84-0.01
-0.05%
FT Vest U.S. Small Cap Moderate Buffer ETF - November (SNOV)
ZECP38.66-0.02
-0.05%
Zacks Earnings Consistent Portfolio ETF (ZECP)
PLU3.00-0.05
-1.48%
Defiance Daily Target 2x Long PL ETF (PLU)